ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26700205.
- Also identified by DOI 10.1158/1078-0432.CCR-15-2549 and PMC identifier 4775407.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Wang and colleagues demonstrate that digital droplet PCR (ddPCR) identified ESR1 mutations in 7% of primary breast cancers. ESR1 mutations were also readily detected in metastatic tissues and circulating tumor DNA in the blood. These results suggest that ddPCR may be amendable for monitoring tumor burden, and to predict relapse. See related article by Wang et al., p. 1130.
Medical subject headings
- Breast Neoplasms
- Neoplasm Recurrence, Local